Related Experiment Video

Updated: May 11, 2026

A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene
08:22

A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene

Published on: September 16, 2019

Factor XIII Val34Leu polymorphism in patients with cardiac syndrome X

Gamze Babur Güler1, Ulaankhuu Batgerel, Ekrem Güler

  • 1Istinye State Hospital, Istanbul, Turkey. gamzebabur@hotmail.com.

Cardiology Journal
|May 17, 2013
PubMed

Insights

The factor XIII Val34Leu polymorphism is more common in patients with cardiac syndrome X (CSX), suggesting a potential genetic link. This finding may aid in understanding CSX risk factors.

Area of Science:

  • Cardiology
  • Genetics
  • Molecular Biology

Background:

  • Cardiac Syndrome X (CSX) is characterized by chest pain despite normal coronary arteries.
  • Understanding the genetic underpinnings of CSX is crucial for risk stratification and management.
  • Factor XIII (FXIII) is involved in hemostasis and may play a role in thrombotic disorders.

Purpose of the Study:

  • To investigate the frequency of factor XIII gene polymorphism in patients diagnosed with cardiac syndrome X.
  • To determine if specific factor XIII variants are associated with an increased risk of developing CSX.

Main Methods:

  • A cross-sectional, observational study involving 48 female CSX patients and 36 age- and gender-matched controls.
  • CSX diagnosis criteria included typical chest pain, abnormal exercise ECG, and angiographically normal coronary arteries.
  • Factor XIII gene polymorphism was analyzed using the CVD Strip Assay commercial kit.

Main Results:

  • The FXIII Val/Leu + Leu/Leu mutation occurred significantly more often in CSX patients (43%) compared to controls (19%) (p=0.02).
  • The Leu allele frequency was also higher in the patient group (23.5% vs. 11.1%, p=0.04).
  • Multivariate analysis identified FXIII Val34Leu mutation (OR=3.42) and smoking (OR=3.33) as independent predictors of CSX.

Conclusions:

  • This study provides evidence supporting an association between the factor XIII Val34Leu polymorphism and cardiac syndrome X.
  • The FXIII Val34Leu variant may represent a genetic risk factor for CSX.
  • Further research is warranted to elucidate the precise mechanisms linking FXIII polymorphism to CSX pathogenesis.
Abstract

More Related Videos

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pleiotropy01:33

Pleiotropy

Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
X-linked Traits01:19

X-linked Traits

In most mammalian species, females have two X sex chromosomes and males have an X and Y. As a result, mutations on the X chromosome in females may be masked by the presence of a normal allele on the second X. In contrast, a mutation on the X chromosome in males more often causes observable biological defects, as there is no normal X to compensate. Trait variations arising from mutations on the X chromosome are called “X-linked”.